IMMX logo

Immix Biopharma, Inc. Stock Price

NasdaqCM:IMMX Community·US$473.4m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author

IMMX Share Price Performance

US$9.30
7.21 (343.91%)
US$9.30
7.21 (343.91%)
Price US$9.30

IMMX Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Excellent balance sheet with slight risk.

4 Risks
1 Reward

Immix Biopharma, Inc. Key Details

US$0

Revenue

US$0

Cost of Revenue

US$0

Gross Profit

US$29.4m

Other Expenses

-US$29.4m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.56
0%
0%
0%
View Full Analysis

About IMMX

Founded
2012
Employees
20
CEO
Ilya Rachman
WebsiteView website
www.immixbio.com

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company’ lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Recent IMMX News & Updates

Recent updates

No updates